Everyone on AGN calling a 300-500 million market cap on its phase 2. When peers after pre clinical were trading 70-100 million market cap after pre clinical success tells you this 10 million market cap and 10 million in funding is funny
Once GLP comes out this month and then runs into a phase 1 study that is for both Stroke and TB which AGN is just for Stroke this is going north of 100 million market cap. The big period is coming shortly
NYR Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
